Tasosartan is an angiotensin II receptor antagonist.

It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.

[1][2]

This drug article relating to the cardiovascular system is a stub.

You can help Wikipedia by expanding it.